Skip to main content

Aimovig Disease Interactions

There are 2 disease interactions with Aimovig (erenumab).


Erenumab (applies to Aimovig) constipation

Moderate Potential Hazard, Moderate plausibility.

Constipation is a common side effect of erenumab therapy and while it is usually mild or moderate in intensity, there have been postmarketing reports of constipation with serious complications including hospitalization and surgery. Onset of constipation was generally after the first dose, although there were reports later in treatment. Patients should be monitored for severe constipation and managed as clinically appropriate. Patients with history of constipation or using medications associated with decreased gastrointestinal motility may be at increased risk for more severe constipation.


  1. (2018) "Product Information. Aimovig (erenumab)." Amgen USA

Erenumab (applies to Aimovig) hypertension

Moderate Potential Hazard, Moderate plausibility.

Hypertension and worsening of preexisting hypertension have been reported in the postmarketing period with erenumab; some patients required pharmacologic treatment and some required hospitalization to control blood pressure. Many patients had preexisting hypertension or risk factors for hypertension. Monitor patients for new onset or worsening hypertension and consider discontinuing therapy if no other cause for hypertension is identified.


  1. (2018) "Product Information. Aimovig (erenumab)." Amgen USA

Aimovig drug interactions

There are 2 drug interactions with Aimovig (erenumab).

Aimovig alcohol/food interactions

There is 1 alcohol/food interaction with Aimovig (erenumab).

Report options

QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.